Group One Trading
XERS icon

Group One Trading’s Xeris Biopharma Holdings XERS Stock Holding History

Group One Trading’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$114K Sell
19,700
-101,100
-84% -$670K ﹤0.01% 4610
2025
Q4 		$948K Sell
120,800
-33,300
-22% -$262K ﹤0.01% 2944
2025
Q3 		$1.25M Buy
154,100
+53,900
+54% +$358K ﹤0.01% 2790
2025
Q2 		$468K Sell
100,200
-155,000
-61% -$710K ﹤0.01% 3488
2025
Q1 		$1.4M Buy
255,200
+100,100
+65% +$404K ﹤0.01% 2157
2024
Q4 		$526K Sell
155,100
-62,600
-29% -$201K ﹤0.01% 3135
2024
Q3 		$620K Buy
217,700
+1,400
+0.6% +$3.6K ﹤0.01% 2699
2024
Q2 		$487K Buy
216,300
+23,000
+12% +$46.4K ﹤0.01% 2588
2024
Q1 		$427K Sell
193,300
-110,400
-36% -$286K ﹤0.01% 2888
2023
Q4 		$714K Sell
303,700
-5,300
-2% -$9.78K ﹤0.01% 2773
2023
Q3 		$575K Buy
309,000
+37,700
+14% +$86.4K ﹤0.01% 2776
2023
Q2 		$711K Buy
271,300
+144,700
+114% +$368K ﹤0.01% 2671
2023
Q1 		$206K Sell
126,600
-578,800
-82% -$725K ﹤0.01% 3644
2022
Q4 		$938K Sell
705,400
-45,600
-6% -$64.4K ﹤0.01% 2471
2022
Q3 		$1.17M Sell
751,000
-40,000
-5% -$66.2K ﹤0.01% 2407
2022
Q2 		$1.22M Buy
791,000
+58,300
+8% +$123K ﹤0.01% 2556
2022
Q1 		$1.88M Sell
732,700
-335,500
-31% -$820K ﹤0.01% 2456
2021
Q4 		$3.13M Sell
1,068,200
-191,100
-15% -$413K ﹤0.01% 2141
2021
Q3 		$3.08M Buy
1,259,300
+333,400
+36% +$968K ﹤0.01% 2213
2021
Q2 		$3.77M Buy
925,900
+168,500
+22% +$643K ﹤0.01% 1975
2021
Q1 		$3.42M Buy
757,400
+493,700
+187% +$2.66M 0.01% 1898
2020
Q4 		$1.3M Buy
263,700
+183,800
+230% +$920K ﹤0.01% 2413
2020
Q3 		$474K Buy
+79,900
New +$319K ﹤0.01% 2899
2019
Q4 		– Sell
-900
Closed -$9K – 5693
2019
Q3 		$9K Buy
+900
New +$10.1K ﹤0.01% 4635

Other funds holding XERS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Group One Trading's XERS Position: Q1 2026 in Review

Group One Trading increased its Xeris Biopharma Holdings (XERS) stake by 77% in Q1 2026, buying an estimated $627K and bringing the position to 218,145 shares worth $1.27M. The position accounts for ﹤0.01% of the portfolio, ranked #2485.

Group One Trading first reported a position in XERS in Q3 2019 and has held it in 12 quarters since. 237 funds tracked by Wall St. Rank hold XERS as of Q1 2026.

  • Group One Trading held 218,145 shares of Xeris Biopharma Holdings worth $1.27M as of Q1 2026.
  • Group One Trading bought 94,584 Xeris Biopharma Holdings shares in Q1 2026, an estimated $627K.
  • Xeris Biopharma Holdings made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #2485 holding.
  • Group One Trading first reported a position in Xeris Biopharma Holdings in Q3 2019 and has held it in 12 quarters since.
  • 237 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.